Cellectis (CLLS) Stock News

Cellectis S.A. (NASDAQ: CLLS) reported that its 49.1% subsidiary, Calyxt, Inc. (NASDAQ: CLXT), announced its Q4 2022 financial results. Calyxt plans to merge with Cibus Global in an all-stock transaction, expected to close in Q2 2023. Calyxt's revenue in Q4 2022 was negligible, down from $1.9 million in Q4 2021, mainly due to the wind-down of its soybean product line. Operating expenses decreased to $3.4 million from $6.6 million year-over-year. Calyxt's cash position was $3.5 million, and with interim funding from Cibus, it will sustain operations through Q2 2023. The merger aims to enhance synergies and innovation in agricultural gene editing.

Calyxt announced a merger with Cibus Global, aiming to create a leading company in gene editing for agriculture. The all-stock transaction allows Calyxt shareholders to retain approximately 5% ownership post-merger, expected to close in Q2 2023, pending shareholder approval. Financial results for Q4 2022 show nominal revenue of $0, down from $1.9 million in Q4 2021, primarily due to the cessation of the soybean product line, while operating expenses decreased to $3.4 million. Notably, Calyxt has secured interim funding from Cibus to sustain operations through Q2 2023. The company continues to progress on key customer projects and technologies.

Cellectis, a clinical-stage biotechnology company, will announce its fourth quarter and year-end 2022 financial results on March 8, 2023, post-market close. A conference call to discuss these results and business updates is scheduled for March 9, 2023, at 8:00 AM ET. Cellectis focuses on developing innovative cell and gene therapies leveraging its gene-editing technology and aims to provide off-the-shelf CAR-T immunotherapies for oncology. The company is headquartered in Paris, with a presence in New York and Raleigh, and is listed on Nasdaq under the ticker CLLS.

Calyxt, Inc. (Nasdaq: CLXT) has filed a Form S-4 with the SEC regarding its merger with Cibus, a leader in precision gene editing in agriculture. Announced on January 17, 2023, the merger is expected to close in the second quarter of 2023, subject to shareholder approval. Following the merger, the new entity will be named Cibus, Inc. and will trade under the ticker symbol CBUS.

This registration statement includes a preliminary proxy statement and prospectus, providing essential details on the merger and its implications. Investors are urged to review these materials once effective.

Cellectis reported its share and voting rights data for January 31, 2023. The company has a total of 45,675,968 shares in capital and 51,743,288 voting rights. Cellectis specializes in gene-editing technology, focusing on innovative CAR-T therapies for cancer treatment and using its TALEN® platform to develop various therapies. Based in Paris, with operations in New York and Raleigh, Cellectis aims to address unmet medical needs through its leading-edge approaches in cell and gene therapies.

Cellectis announced the initial closing of an underwritten global offering on February 7, 2023, involving 8,800,000 American Depositary Shares (ADSs) at an offering price of $2.50 each, raising gross proceeds of approximately $24.77 million. Additionally, underwriters exercised an option for 1,107,800 additional ADSs, expected to close on February 8, 2023. The net proceeds will primarily support the clinical development of its UCART therapies. Following these transactions, Cellectis anticipates sufficient funds to operate until Q2 2024. The offering was based on the average trading price of the ordinary shares, minus a discount.

Cellectis S.A. (NASDAQ: CLLS) has announced a global offering of 8,800,000 American Depositary Shares (ADS) at a public price of $2.50 per ADS, initiated on February 2, 2023. The offering is set to close around February 7, 2023, pending usual closing conditions. Major shareholders, including Bpifrance and Baillie Gifford, will receive a significant portion of the offering. The company's ordinary shares were temporarily suspended on Euronext Growth on February 3, with trading expected to resume later that day. As a biotechnology entity, Cellectis focuses on gene-editing technologies to develop innovative therapies for various diseases.

Cellectis S.A. has launched an underwritten global offering of 8,800,000 American Depositary Shares (ADS) at $2.50 each, aimed at raising approximately $20.2 million post-expenses. The proceeds are intended for clinical development of UCART therapies and general corporate purposes. The offering, scheduled to close on February 7, 2023, will lead to a dilution of approximately 16.2% of existing shares. The offered ADSs will commence trading on the Nasdaq Global Market. Jefferies and Barclays are the joint book-running managers for the offering, which is backed by a 30-day option for underwriters to purchase additional shares. These steps follow Cellectis' strategy to fund its cell and gene therapy advancements.

Cellectis, a clinical-stage biotechnology company focused on gene-editing therapies, has launched a global offering of $22 million in American Depositary Shares (ADS). Each ADS represents one ordinary share, with a nominal value of €0.05. The offering includes a public offering in the U.S. and a private placement for qualified investors in other countries. Proceeds will support the clinical development of several product candidates and general corporate purposes. The offering size and price will be determined through an accelerated bookbuilding process. Cellectis has been granted the option for underwriters to purchase an additional 15% of the offering.